Comparative Effectiveness of Several Second-Line Dual Oral Antidiabetic Combinations in Reducing Cardiovascular Events in Type 2 Diabetes-A Nationwide Study

被引：0
|
作者：
Chang, Chia-Hsuin
Chang, Yi-Cheng
Lin, Jou-Wei
Chen, Shu-Ting
Lai, Mei-Shu
Chuang, Lee-Ming
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2408-PO
引用
收藏
页码：A611 / A611
页数：1
相关论文
共 50 条
  • [21] Risk of Major Cardiovascular Events during Second-Line Antidiabetic Treatments: A Population-Based Cohort Study
    Zghebi, Salwa S.
    Steinke, Douglas T.
    Rutter, Martin K.
    Emsley, Richard A.
    Ashcroft, Darren M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 555 - 556
  • [22] The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study
    Kim, Won Jun
    Noh, Jung Hyun
    Han, Kyungdo
    Park, Cheol-Young
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 81 (03) : 1263 - 1272
  • [23] Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes
    Heo, Chan Uk
    Choi, Chang-Ik
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (03)
  • [24] SECOND-LINE ANTIDIABETIC AGENT ORDER PATTERNS IN PATIENTS WITH TYPE 2 DIABETES ACROSS HEALTHPLAN TYPES
    Kim, S.
    Kim, K.
    VALUE IN HEALTH, 2024, 27 (06) : S242 - S242
  • [25] The Comparative Cardiovascular Effectiveness of Six Antidiabetic Medications among Insured Adults with Type 2 Diabetes
    O'Brien, Matthew
    Karam, Susan L.
    Wallia, Amisha
    Kang, Raymond
    Cooper, Andrew J.
    Lancki, Nicola
    Moran, Margaret R.
    Liss, David T.
    Prospect, Theodore A.
    Ackermann, Ronald T.
    DIABETES, 2018, 67
  • [26] Vascular events in patients with type 2 diabetes in the year following initiation of second-line therapy: the DISCOVER study
    Surmont, F.
    Chen, H.
    Cid-Ruzafa, J.
    Fenici, P.
    Gomes, M. B.
    Khunti, K.
    Pocock, S.
    Rathmann, W.
    Shestakova, M. V.
    Shimomura, I.
    Tang, F.
    Watada, H.
    Ji, L.
    Hammar, N.
    Kosiborod, M.
    DIABETOLOGIA, 2018, 61 : S562 - S562
  • [27] Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus A Cohort Study
    Roumie, Christianne L.
    Hung, Adriana M.
    Greevy, Robert A.
    Grijalva, Carlos G.
    Liu, Xulei
    Murff, Harvey J.
    Elasy, Tom A.
    Griffin, Marie R.
    ANNALS OF INTERNAL MEDICINE, 2012, 157 (09) : 601 - +
  • [28] Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data
    Bidulka, Patrick
    Lugo-Palacios, David G.
    Carroll, Orlagh
    O'Neill, Stephen
    Adler, Amanda, I
    Basu, Anirban
    Silverwood, Richard J.
    Bartlett, Jonathan W.
    Nitsch, Dorothea
    Charlton, Paul
    Briggs, Andrew H.
    Smeeth, Liam
    Douglas, Ian J.
    Khunti, Kamlesh
    Grieve, Richard
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 385
  • [29] Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes
    Franchi, Matteo
    Pellegrini, Giacomo
    Avogaro, Angelo
    Buzzetti, Giuliano
    Candido, Riccardo
    Cavaliere, Arturo
    Consoli, Agostino
    Marzona, Irene
    Mennini, Francesco Saverio
    Palcic, Stefano
    Corrao, Giovanni
    BMJ OPEN DIABETES RESEARCH & CARE, 2024, 12 (03)
  • [30] Vascular Events in Patients with Type 2 Diabetes in the Year following Initiation of Second-Line Therapy-The DISCOVER Study
    Kosiborod, Mikhail
    Chen, Hungta
    Cid-Ruzafa, Javier
    Fenici, Peter
    Gomes, Marilia B.
    Khunti, Kamlesh
    Pocock, Stuart
    Rathmann, Wolfgang
    Shestakova, Marina V.
    Shimomura, Iichiro
    Surmont, Filip
    Tang, Fengming
    Watada, Hirotaka
    Ji, Linong
    Hammar, Niklas
    DIABETES, 2018, 67
12345